Evidence map›Paper›PMID 29531365›Full record

ArticleNature microbiology2018

The TRiC chaperonin controls reovirus replication through outer-capsid folding.

Jonathan J Knowlton, Isabel Fernández de Castro, Alison W Ashbrook, Daniel R Gestaut, Paula F Zamora, Joshua A Bauer, J Craig Forrest, Judith Frydman, Cristina Risco, Terence S Dermody

Abstract read
In one paragraph

Article in Nature microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Protein folding by the CCT/TRiC chaperone complex.Current opinion in structural biology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Jonathan J KnowltonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0002-1630-8734
Isabel Fernández de CastroNational Center for Biotechnology, Spanish National Research Council, CNB-CSIC, Madrid, Spain.
Alison W AshbrookDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Daniel R GestautDepartment of Biology, Stanford University, Palo Alto, CA, USA.
Paula F ZamoraDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Joshua A BauerDepartment of Biochemistry, Institute of Chemical Biology, High-Throughput Screening Facility, Vanderbilt University School of Medicine, Nashville, TN, USA.
J Craig ForrestDepartment of Microbiology and Immunology, Center for Microbial Pathogenesis and Host Responses, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Judith FrydmanDepartment of Biology, Stanford University, Palo Alto, CA, USA.
Cristina RiscoNational Center for Biotechnology, Spanish National Research Council, CNB-CSIC, Madrid, Spain.
Terence S DermodyDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. terence.dermody@chp.edu.ORCID 0000-0003-1853-8741
University of Pittsburgh · USConsejo Superior de Investigaciones Científicas · ESPalo Alto University · USVanderbilt University · USUniversity of Arkansas for Medical Sciences · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
CELL ENTRY OF REOVIRUSR01AI032539 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TERENCE S. DERMODY · 1998 to 2026
$12.3M
Mechanism of the Eukaryotic Chaperonin TRiC/CCTR01GM074074 · NIGMS · STANFORD UNIVERSITY · PI FRYDMAN, JUDITH · 2005 to 2024
$6.8M
Defining the role of Host Hsp70 Subnetworks in Dengue Virus ReplicationR01AI127447 · NIAID · STANFORD UNIVERSITY · PI FRYDMAN, JUDITH · 2017 to 2021
$2.4M
Mechanisms of noncytolytic reovirus egressF30AI122563 · NIAID · VANDERBILT UNIVERSITY · PI KNOWLTON, JONATHAN JAMES · 2016 to 2019
$153k
NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NIAID NIH HHS F30 AI122563NIAID NIH HHS R01 AI032539NIAID NIH HHS R01 AI127447NIGMS NIH HHS R01 GM074074NIGMS NIH HHS T32 GM007347
6 · The paper itself

Abstract

Viruses are molecular machines sustained through a life cycle that requires replication within host cells. Throughout the infectious cycle, viral and cellular components interact to advance the multistep process required to produce progeny virions. Despite progress made in understanding the virus-host protein interactome, much remains to be discovered about the cellular factors that function during infection, especially those operating at terminal steps in replication. In an RNA interference screen, we identified the eukaryotic chaperonin T-complex protein-1 (TCP-1) ring complex (TRiC; also called CCT for chaperonin containing TCP-1) as a cellular factor required for late events in the replication of mammalian reovirus. We discovered that TRiC functions in reovirus replication through a mechanism that involves folding the viral σ3 major outer-capsid protein into a form capable of assembling onto virus particles. TRiC also complexes with homologous capsid proteins of closely related viruses. Our data define a critical function for TRiC in the viral assembly process and raise the possibility that this mechanism is conserved in related non-enveloped viruses. These results also provide insight into TRiC protein substrates and establish a rationale for the development of small-molecule inhibitors of TRiC as potential antiviral therapeutics.

Indexed as

AnimalsCaco-2 CellsCapsidCapsid ProteinsCell Line, TumorChaperonin Containing TCP-1Endothelial CellsHEK293 CellsHigh-Throughput Screening AssaysHumansMiceOrthoreovirus, MammalianProtein FoldingRNA InterferenceRNA, Small InterferingVirus AssemblyCapsid ProteinsChaperonin Containing TCP-1RNA, Small Interfering

Identifiers

PMID29531365
PMCPMC5874176
OpenAlexW2791785408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.